1.18
price up icon4.42%   0.05
after-market Dopo l'orario di chiusura: 1.21 0.03 +2.54%
loading
Precedente Chiudi:
$1.13
Aprire:
$1.13
Volume 24 ore:
2.21M
Relative Volume:
0.70
Capitalizzazione di mercato:
$319.35M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.5566
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
-5.60%
1M Prestazione:
+0.85%
6M Prestazione:
-44.60%
1 anno Prestazione:
-49.36%
Intervallo 1D:
Value
$1.11
$1.23
Intervallo di 1 settimana:
Value
$1.11
$1.275
Portata 52W:
Value
$0.8621
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Nome
Allogene Therapeutics Inc
Name
Telefono
(650) 457-2700
Name
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
361
Name
Cinguettio
@AllogeneTx
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
ALLO's Discussions on Twitter

Confronta ALLO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.18 319.35M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 Aggiornamento Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 Ripresa Oppenheimer Outperform
2024-05-31 Iniziato Piper Sandler Overweight
2024-01-05 Downgrade Guggenheim Buy → Neutral
2024-01-05 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 Iniziato Citigroup Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-01-24 Aggiornamento JP Morgan Neutral → Overweight
2023-01-06 Aggiornamento Robert W. Baird Neutral → Outperform
2022-12-12 Downgrade BofA Securities Buy → Underperform
2022-08-10 Downgrade Raymond James Outperform → Mkt Perform
2022-07-15 Aggiornamento Goldman Neutral → Buy
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-28 Reiterato B. Riley Securities Buy
2021-10-20 Iniziato Cowen Outperform
2021-10-08 Downgrade Goldman Buy → Neutral
2021-10-08 Downgrade Stifel Buy → Hold
2021-09-23 Aggiornamento Raymond James Mkt Perform → Outperform
2021-06-21 Ripresa Jefferies Buy
2021-05-20 Aggiornamento Truist Hold → Buy
2021-05-14 Iniziato B. Riley Securities Buy
2021-01-26 Aggiornamento Stifel Hold → Buy
2020-12-10 Ripresa H.C. Wainwright Buy
2020-11-24 Iniziato BofA Securities Buy
2020-10-23 Iniziato RBC Capital Mkts Outperform
2020-06-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-29 Reiterato H.C. Wainwright Buy
2020-05-19 Aggiornamento ROTH Capital Neutral → Buy
2020-05-15 Aggiornamento Guggenheim Neutral → Buy
2020-05-14 Reiterato H.C. Wainwright Buy
2020-05-14 Downgrade SunTrust Buy → Hold
2020-04-13 Iniziato SunTrust Buy
2020-03-13 Iniziato H.C. Wainwright Buy
2020-03-05 Iniziato Stifel Hold
2020-02-24 Iniziato Berenberg Hold
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-11-04 Iniziato Canaccord Genuity Buy
2019-08-09 Iniziato BTIG Research Buy
2019-06-05 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Neutral
2019-05-23 Iniziato Stifel Hold
2019-03-29 Iniziato Piper Jaffray Overweight
Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st

Jun 12, 2025
pulisher
Jun 04, 2025

Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News

Jun 04, 2025
pulisher
Jun 03, 2025

Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - MarketScreener

Jun 01, 2025
pulisher
May 29, 2025

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

May 28, 2025
pulisher
May 28, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 28, 2025
pulisher
May 27, 2025

Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada

May 27, 2025
pulisher
May 26, 2025

Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com

May 26, 2025
pulisher
May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail

May 24, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st

May 22, 2025
pulisher
May 22, 2025

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

May 22, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 17, 2025

Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025
pulisher
May 15, 2025

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 15, 2025

Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):